A functional RNase P ribozyme (M1GS RNA) was constructed to target the overlapping mRNA region of two murine cytomegalovirus (MCMV) capsid proteins essential for viral replication: the assembly protein (mAP) and M80. The customized ribozyme efficiently cleaved the target mRNA sequence in vitro. Moreover, 80% reduction in the expression of mAP and M80 and a 2,000-fold reduction in viral growth were observed in cells expressing the ribozyme. In contrast, there was no significant reduction in viral gene expression and growth in cells that either did not express the ribozyme or produced a ''disabled'' ribozyme carrying mutations that abolished its catalytic activity. When the ribozyme-expressing constructs were delivered into MCMV-infected SCID mice via a modified ''hydrodynamic transfection'' procedure, expression of ribozymes was observed in the livers and spleens. Compared with the control animals that did not receive any M1GS constructs or received the disabled ribozyme construct, animals receiving the functional ribozyme construct exhibited a significant reduction of viral gene expression and infection. Viral titers in the spleens, livers, lungs, and salivary glands of the functional ribozyme-treated SCID mice at 21 days after infection were 200-to 2,000-fold lower than those in the control animals. Moreover, survival of the infected animals significantly improved upon receiving the functional ribozyme construct. Our study examines the use of M1GS ribozymes for inhibition of gene expression in animals and demonstrates the utility of RNase P ribozymes for gene targeting applications in vivo.
A functional RNase P ribozyme (M1GS RNA) was constructed to target the overlapping mRNA region of two murine cytomegalovirus (MCMV) capsid proteins essential for viral replication: the assembly protein (mAP) and M80. The customized ribozyme efficiently cleaved the target mRNA sequence in vitro. Moreover, 80% reduction in the expression of mAP and M80 and a 2,000-fold reduction in viral growth were observed in cells expressing the ribozyme. In contrast, there was no significant reduction in viral gene expression and growth in cells that either did not express the ribozyme or produced a ''disabled'' ribozyme carrying mutations that abolished its catalytic activity. When the ribozyme-expressing constructs were delivered into MCMV-infected SCID mice via a modified ''hydrodynamic transfection'' procedure, expression of ribozymes was observed in the livers and spleens. Compared with the control animals that did not receive any M1GS constructs or received the disabled ribozyme construct, animals receiving the functional ribozyme construct exhibited a significant reduction of viral gene expression and infection. Viral titers in the spleens, livers, lungs, and salivary glands of the functional ribozyme-treated SCID mice at 21 days after infection were 200-to 2,000-fold lower than those in the control animals. Moreover, survival of the infected animals significantly improved upon receiving the functional ribozyme construct. Our study examines the use of M1GS ribozymes for inhibition of gene expression in animals and demonstrates the utility of RNase P ribozymes for gene targeting applications in vivo.
cytomegalovirus ͉ gene targeting ͉ herpesvirus ͉ antisense H uman cytomegalovirus (CMV), a common opportunistic pathogen, causes significant morbidity and mortality in immunocompromised or immunologically immature individuals, including neonates, AIDS patients, and transplant recipients (1) . The emergence of drug-resistant strains of CMV has posed a need for the development of new drugs and treatment strategies. Murine cytomegalovirus (MCMV) infection of mice resembles its human counterpart with respect to pathogenesis, thus providing an animal model for studying CMV infection in vivo and for screening novel agents and developing new antiviral approaches (1) (2) (3) (4) . For example, the CB17 SCID mice, which lack functional T and B lymphocytes, are highly susceptible to MCMV infection (5, 6) . Analysis of viral replication in these mice can be used for studying whether new therapeutic approaches block CMV opportunistic infection and prevent viral-associated diseases in immunocompromised hosts.
Nucleic acid-based gene interference technologies represent promising gene-targeting strategies for specific inhibition of mRNA sequences of choice (7) (8) (9) . For example, ribozymes have been shown to cleave viral mRNA sequences and inhibit viral replication in human cells (10) . More recently, siRNAs were proven to be effective in inducing endogenous RNase of the RNA-induced silencing complex (RISC) in the RNAi pathway to inhibit gene expression and growth of several human viruses (7, 11, 12) . Thus, nucleic-acid-based gene interference approaches can be used as a tool in both basic and clinical research, such as in studies of tumorigenesis and antiviral gene therapy.
RNase P is a ribonucleoprotein complex responsible for the 5Ј maturation of tRNA (13, 14) . Altman and colleagues (13) have previously shown that RNase P of Escherichia coli contains a catalytic RNA subunit (M1 RNA) that can be engineered to cleave tRNA substrates and other target RNAs, including specific mRNAs (13) (14) (15) (16) . A sequence-specific ribozyme, M1GS, constructed by attaching M1 RNA to a guide sequence complementary to a target mRNA ( Fig. 1 A and B ) is effective in blocking mRNA expression in cultured cells (17, 18) . Unlike other nucleic-acid-based interference approaches, such as antisense oligonucleotides and RNAi (7, 8) , M1GS-based strategy is unique because of the use of M1 RNA, one of the most efficient catalytic RNAs found in nature (13, 14) . Previous studies have shown that M1GS RNA and RNase P are effective in cleaving both viral and cellular mRNAs and blocking their expression in cultured cells, including inhibition of gene expression of human influenza and herpes viruses (9, (18) (19) (20) . However, it has not been reported whether M1GS RNAs also function to inhibit gene expression in vivo in animals.
Using MCMV infection of mice as the model, in this study we provide direct evidence that M1GS RNA is effective in inhibiting viral gene expression and blocking viral infection and pathogenesis, leading to improved survival of animals. M1GS ribozymes were constructed to target the region of the mRNA encoding MCMV capsid assembly protein (mAP). The mAP coding sequence completely overlaps with and is within the 3Ј coding sequence of another viral capsid protein, M80 (21) . Both mAP and M80 are essential for viral capsid formation and CMV replication (22, 23) . We showed that the constructed ribozymes efficiently cleaved the target mRNA sequence in vitro and effectively inhibited mAP expression and viral growth in cultured cells. When constructs carrying M1GS expression cassettes were introduced to MCMV-infected SCID mice via a modified hydrodynamic transfection procedure (24 -26) , viral gene expression and growth in various organs of these animals were reduced and animal survival significantly improved. In addition to investigating the activity of M1GS ribozymes in animals, our study demonstrates the feasibility of developing effective RNase P ribozymes as a novel class of antiviral agents for treatment of viral diseases in vivo.
Results

M1GS-Mediated
Cleavage of the mAP mRNA Sequence in Vitro. The mRNA (mAP mRNA) encoding the mAP and the M80 mRNA coterminate at the same 3Ј polyadenenylation site (21, 27) . M1GS-mediated cleavage at the overlapping region of the M80 and mAP mRNAs is expected to block the expression of both mRNAs simultaneously and should lead to a significant reduction of MCMV growth. To choose a targeted region that is accessible to binding of ribozymes to achieve efficient cleavage, we used an in vivo mapping Author contributions: Y.B., P.T., H.L., K.K., T.Z., and F.L. designed research, performed research, contributed new reagents/analytic tools, analyzed data, and wrote the paper. approach with DMS (18, 28) to determine the accessibility of the region of the mAP mRNA in MCMV-infected cells. A position 88 nucleotides downstream from the mAP translational initiation codon (29) was chosen as the cleavage site for M1GS RNA. This site appears to be one of the regions most accessible to DMS modification and presumably to ribozyme binding (30) .
Ribozyme M1-1 was constructed by covalently linking the 3Ј terminus of M1 RNA with a guide sequence of 18 nucleotides that is complementary to the targeted mAP mRNA sequence. The control ribozyme, M1-2, was constructed in a similar way and derived from C102 RNA, a M1 mutant that contained several point mutations at the P4 domain and was at least 10 4 -fold less active than M1 RNA in cleaving a pretRNA (31) . M1-1 and M1-2 were synthesized in vitro from DNA coding for these ribozymes and were incubated with substrate Map39, which contained the targeted mAP mRNA sequence of 39 nucleotides (Fig. 1C) . Cleavage of Map39 by M1GS yielded two cleavage products of 12 and 27 nucleotides, respectively (Fig. 1C) . Efficient cleavage of Map39 by M1-1 was observed (Fig. 1D, lane 2) , whereas cleavage by M1-2 was barely detected (Fig. 1D, lane 3) . The differential cleavage efficiencies observed for M1-1 and M1-2 may not be a result of their different binding affinities to the mAP mRNA sequence, because experiments with gel-shift assays indicated that the binding affinity of M1-2 to Map39 (K d ϭ 0.30 Ϯ 0.04 nM) is similar to that of M1-1 (K d ϭ 0.34 Ϯ 0.05 nM). Because M1-2 contains the same antisense guide sequence and similar affinity to Map39 as M1-1 but is catalytically inactive, this ribozyme can be used as a control for the antisense effect in our experiments in cultured cells.
Efficient Expression of the Ribozymes in Cells. The DNA sequences coding for M1-1 and M1-2 were cloned into retroviral vector LXSN and placed under the control of the small nuclear U6 RNA promoter, which has previously been shown to express M1GS RNA and other RNAs efficiently (18, 32, 33) . To construct cell lines that express M1GS ribozymes, amphotropic packaging cells (PA317) (33) were transfected with LXSN-M1GS DNA to produce retroviral vectors that contained the genes for M1GS RNA. NIH 3T3 cells were then infected with these vectors, and cells expressing the ribozymes were cloned.
An additional cell line that expressed ribozyme M1-TK, a ribozyme targeting the mRNA for the thymidine kinase of HSV-1 (18), was also constructed. No cleavage of Map39 by M1-TK was observed in vitro (Fig. 1D, lane 4) . We used this cell line to determine whether M1GS RNA with an incorrect guide sequence could target mAP mRNA in tissue culture. The level of M1GS RNA in each cell clone was determined by Northern analysis, using the expression of mouse RNase P RNA (mP1 RNA) as the internal control ( Fig. 1 E and F) (34, 35) . We only used the cell lines that expressed similar levels of these ribozymes for further studies. The constructed lines and a control line in which cells were transfected with LXSN vector DNA alone were indistinguishable in terms of their growth and viability for Յ3 months (data not shown), suggesting that the expression of the ribozymes did not result in significant cytotoxicity.
Inhibition of MCMV Gene Expression and Growth by M1GS Ribozymes
in Cultured Cells. To determine the efficacy of the ribozymes in inhibiting the expression of MCMV mAP and M80, cells were infected with MCMV at a multiplicity of infection (MOI) of 0.1 to 1. Total RNAs were isolated from the infected cells at 8-72 h after infection. The expression levels of mAP and M80 mRNAs were determined by Northern analyses. The level of the 7.2-kb-long viral transcript (7.2-kb RNA), whose expression is not regulated by mAP or M80 under the assay conditions (36) , was used as an internal control for the quantitation of expression of mAP and M80 mRNAs (Fig. 2 A) . A reduction of 80 Ϯ 7% and 80 Ϯ 8% (average of three experiments) in the expression level of M80 and mAP mRNA was observed in cells that expressed M1-1, respectively (Table 1) . In contrast, a reduction of Ͻ10% in the expression level of these two mRNAs was observed in cells that expressed M1-2 or M1-TK. These results suggest that the significant reduction of mAP mRNA expression in cells that expressed M1-1 was because of the targeted cleavage by the ribozyme. The low level of inhibition found in cells that expressed M1-2 was presumably because of an antisense effect, (25 g) were separated on 2% agarose gels that contained formaldehyde, transferred to nitrocellulose membranes, and hybridized to a [ 32 P]-radiolabeled probe that contained the DNA sequence coding for M1 RNA (lanes 5-7) (E) or mP1 RNA (lanes 8 -10) (F), the RNA subunit of mouse RNase P (34, 35) . The hybridized products corresponding to the full-length retroviral transcripts (Ϸ6kb), transcribed from the LTR promoter, are at the top of the gel and are not shown. because M1-2 exhibits similar binding affinity to the target sequence as M1-1 but is catalytically inactive.
The protein expression of mAP was determined by using Western analysis (Fig. 2D ) with the expression of actin as the internal control (Fig. 2C) . The results of three independent experiments are summarized in Table 1 . A reduction of Ϸ84% in the level of mAP protein was observed in cells that expressed M1-1 RNA. In contrast, a reduction of Ͻ10% was found in cells that expressed M1-2 or M1-TK RNA. The low level of reduction in the expression level of mAP protein observed in cells that expressed M1-2 was probably because of the antisense effect of the guide sequence.
To determine whether the growth of MCMV is inhibited in the ribozyme-expressing cells, cells were infected by MCMV at an MOI of 1. Virus stocks were prepared from the infected cultures (cells and culture medium together) at 1-day intervals through 5 days after infection, and their titers were determined. At 4 days after infection, a reduction of at least 2,000-fold in viral yield was observed in cells that expressed M1-1 (Fig. 2E) . No significant reduction was found in those that expressed M1-2 or M1-TK (Fig. 2E) . These results suggest that M1GS-mediated targeting of viral mAP mRNA effectively inhibits MCMV growth. There was no significant difference in the level of inhibition of viral AP gene expression and growth among different cloned cell lines that expressed M1-1.
Inhibition of MCMV Infection and Pathogenesis by M1GS Ribozymes in
Animals. Immunodeficient animals, such as SCID mice, have been shown to be extremely susceptible to MCMV infection (1, 5, 6) . To determine the effect of M1GS ribozymes on the replication and infection of MCMV in vivo, we applied hydrodynamic transfection (24-26) of plasmid LXSN-M1GS DNA to SCID mice that had been i.p. infected 24 h earlier with MCMV. To further allow sustained expression of M1GSs in these animals, a similar hydrodynamic transfection procedure was repeated every 72 h. Transfection efficiency was assessed by detecting the expression of M1GS RNAs in the tissues (Fig. 3 A and B ) and the expression of GFP, whose coding sequence is included in the LXSN vector (data not shown). Consistent with previous hydrodynamic transfection reports (24) (25) (26) , the transfection appeared to be efficient as substantial amount of M1GS (Fig. 3B) and GFP-positive (data not shown) cells were found in the livers and spleens of the animals.
Three sets of experiments were carried out to study the effect of M1GS on viral virulence and infection in vivo. First, the survival rate of the animals that received the M1-1-expressing plasmid was determined and compared to animals that received only PBS or PBS with the M1-2-or M1-TK-containing constructs. All noninfected animals that received M1GS-LXSN constructs via the hydrodynamic transfection procedure remained alive and exhibited no adverse signs for at least 90 days as compared with untreated noninfected animals (data not shown). Transfection of the M1-2 or M1-TK constructs had no effect on the survival of infected animals compared with those that received PBS only, because all of the mice died within 26-27 days after infection (Fig. 4) . In contrast, in infected mice expressing M1-1 life span improved significantly, because no animals died until 40 days after infection (Fig. 4) .
To further study the effect of M1GS expression in MCMV infection of these immunodeficient animals, viral replication in various organs of the animals was studied during a 21-day infection period before the onset of mortality of the infected animals. In these experiments, SCID mice were infected i.p. with 1 ϫ 10 4 pfu MCMV and then injected with different plasmids via tail veins using a hydrodynamic transfection procedure. The transfection procedure was repeated every 72 h. At 1, 3, 7, 10, 14, and 21 days after Levels of inhibition of viral gene expression in cells that  expressed M1-1, M1-2 , and M1-TK, as compared to The values shown are the means of triplicate experiments, and the values of standard deviation that were Ͻ5% are not shown.
infection, animals were killed and the spleens, livers, lungs, and salivary glands were harvested (5) . The viral titers in each of the organs from animals receiving either M1-2 or M1-TK were similar to those in animals that received only PBS (Fig. 5 A-D) . In contrast, the titers in animals receiving M1-1 were consistently lower at every time point examined. At 21 days after infection, the viral titers in the spleens, livers, lungs, and salivary glands of the M1-1-treated animals were lower than those from animals receiving no M1GS constructs by 200-, 400-, 1,000-and 2,000-fold, respectively (Fig. 5  A-D) . These results suggest that the expression of M1-1 inhibits viral infection in vivo, including in the spleen and liver. Viral gene expression in the tissues was also examined. At 14 days after infection, the expression of viral M80 and mAP mRNA, as well as the mAP protein, was readily detectable in the livers and spleens of mice receiving control M1-2 and M1-TK constructs, whereas no appreciable expression was detected at this time point in M1-1-treated mice (Fig. 3 and data not shown) . More importantly, no difference could be detected between mice that received no M1GS constructs and those that received the control constructs M1-2 or M1-TK (Fig. 3) . These results are consistent with the notion that MCMV infection is inhibited in animals receiving the M1-1-expressing plasmid.
Discussion
Nucleic-acid-based gene interference strategies, such as antisense oligonucleotides, ribozymes or DNAzymes, and RNAi represent powerful research tools and promising therapeutic agents against human diseases (7, 9, 12) . For example, siRNAs are effective in inducing RNAi to inhibit gene expression in vitro and in vivo (7, 11, 25) . Each of these approaches has its own advantages and limitations in terms of targeting efficacy, sequence specificity, toxicity, and delivery efficiency in vivo. The M1GS-based technology represents an attractive approach for gene inactivation because it generates catalytic and irreversible cleavage of the target RNA by using M1 RNA, a highly active RNA enzyme found in nature (13, 14) . These properties, as well as the simple design of the guide sequence, make M1GS an attractive gene-targeting agent that can be generally used for antiviral and other in vivo applications. For M1GS ribozyme to be successful as a therapeutic tool for practical applications, the enzyme has to be highly active and stable in tissues and effective in blocking gene expression in vivo.
In the current study, we have designed a M1GS RNA targeting the overlapping region of MCMV mAP and M80 mRNA. The ribozyme cleaved the target mRNAs efficiently in vitro and, furthermore, reduced their expression levels by 80-85% and inhibited viral growth by 2,000-fold in cells that expressed the ribozyme. In contrast, a reduction of Ͻ10% in the levels of mAP expression and viral growth was observed in cells that expressed M1-2 or M1-TK. When MCMV-infected SCID mice were injected with plasmids carrying different M1GS-LXSN DNA via a hydrodynamic transfection procedure, the expression of M1GS RNAs was detected in several tissues, including the spleen and liver. All animals that received PBS only or PBS with the M1-2 or M1-TK constructs died within 27 days after infection, whereas those receiving M1-1 remained alive until 40 days after infection. In contrast, all noninfected animals that received M1GS-LXSN constructs via a hydrodynamic transfection procedure remained alive and exhibited no adverse signs for at least 90 days, as compared with untreated noninfected animals (data not shown). Furthermore, viral titers found in the spleens, livers, lungs, and salivary glands of the animals receiving the M1-1 construct were significantly lower than those in animals that received PBS only or PBS with the M1-2 or M1-TK constructs. M1-TK targets an unrelated mRNA, and M1-2 is catalytically inactive and contains the identical guide sequence to M1-1. Thus, the observed reduction in viral gene expression and inhibition of viral growth in the M1-1-expressing cells and in animals is primarily attributed to the specific targeted cleavage by the ribozyme, as opposed to the antisense effect of the guide sequence.
Our results also provide direct evidence that suggests that MGS RNAs are active and specific in vivo in animals. First, M1GS RNAs were readily detected in cultured cells and in the livers of the animals. Second, there are no significant differences in terms of growth and viability of the constructed ribozyme-expressing cell lines and the parental cells for up to 3 months. Noninfected animals 6, 10, 14, and 18 ). Equal amounts of each RNA sample (50 g) were separated on agarose gels that contained formaldehyde, transferred to nitrocellulose membranes, and hybridized to [ 32 P]-radiolabeled probes that contained the sequence of the mP1 (lanes 1-3) , M1 RNA (lanes 4 -6), and mAP mRNA (lanes 7-10). For Western analyses, equal amounts of protein samples (80 g) were separated in SDS-polyacrylamide gels. The membranes were stained with the antibodies against mouse actin (D) and MCMV mAP (E). Fig. 4 . Mortality of the SCID mice infected with the Smith strain, followed by hydrodynamic transfection of PBS alone and PBS with different M1GS-LXSN DNA (M1-1, M1-2, and M1-TK). CB17 SCID mice (five animals per group) were infected i.p. with 1 ϫ 10 4 pfu MCMV 24 h before hydrodynamic transfection. The transfection procedure was repeated every 72 h. Mortality of mice was monitored for at least 41 days after infection, and survival rates were determined.
that received M1GS-LXSN constructs via a hydrodynamic transfection procedure exhibited no adverse signs for 90 days when compared with animals receiving only PBS (data not shown). These results suggest that the ribozymes do not significantly interfere with cellular gene expression and that expression of the ribozymes does not exhibit significant cytotoxicity both in vitro and in vivo. Third, M1GS RNA only inhibits the expression of mAP/M80. No reductions in the expression levels of other viral genes examined (e.g., mie1, M99, and m155) were observed in M1GS-expressing cells (Table 1) . Fourth, the ribozymes appear to be active in cleaving the target mAP mRNA in vivo in animals. Reduced mAP expression, decreased viral titers, and increased survival were found in animals that received M1-1-expressing constructs but not in animals that received PBS only or PBS with the M1-2 or M1-TK constructs. These results suggest that M1GS-mediated cleavage of its target mAP mRNA in vivo is effective and specific, resulting in a decreased expression of mAP and inhibition of viral growth, leading to blocking viral infection and increasing survival of infected animals.
Human CMV is a member of the herpes virus family, which includes other different viruses such as HSV and EBV (1). This virus causes significant morbidity and mortality in immunoimmature or immunodeficient individuals, such as organ transplant recipients. MCMV infection of SCID mice represents an excellent animal model to study CMV pathogenesis in immunocompromised hosts and to assess efficacy of novel antivirals for blocking viral infection and virulence. I.p. infection of SCID mice leads to a biphasic infection, initially with viral infection and replication in the spleen and liver, followed by dissemination of the virus via leukocyte-associated viremia from the spleen and liver to other peripheral organs, such as the lungs and salivary glands (1-3). SCID mice are highly susceptible to MCMV and can succumb to as little as 10 pfu of the virus, primarily because of liver damage and failure associated with viral lytic replication in the organ (1, 3, 6 ). Hydrodynamic transfection procedure via tail vein injection, which was used in our study, has been shown to deliver plasmid DNA efficiently and rapidly to the liver and spleen and to allow efficient expression of the transfected genes in these organs (24) (25) (26) . Our results indicate substantial expression of M1GS RNAs in the liver and spleen. Furthermore, viral gene expression in the liver was found to be substantially reduced in M1-1-expressing plasmidtreated mice. During a 21-day time course infection, viral titers in the spleens, livers, lungs, and salivary glands of the animals receiving the M1-1 construct were lower than those in animals that received PBS only or PBS with the M1-2 or M1-TK constructs. These results suggest that the delivery of M1GS-LXSN DNAs and the subsequent expression of M1GS RNA in the spleen and liver resulted in the inhibition of viral initial infection in these two organs, leading to an overall diminished systemic infection and viral dissemination in other organs, including the lungs and salivary glands. The improved survival of animals receiving M1-1 is probably because of the lower viral load found in the livers of these animals. This notion is consistent with the observation that a high level of viral lytic replication and production usually leads to severe damage of hepatic tissues and liver failure and contributes significantly to MCMV virulence and killing of SCID mice (1, 2, 5) . Thus, our results suggest that inhibiting viral infection in the spleen and liver may significantly block viral systemic infection in other organs and increase host survival.
To successfully use M1GS for clinical applications, the ribozymes need to be delivered specifically into target tissues and cell types in vivo. The hydrodynamic transfection method is useful to demonstrate the feasibility of delivering novel transgenes and compounds into animals and to test their activity in vivo (24) (25) (26) . However, it is not suitable for clinical applications. CMV establishes latent infection in bone marrow progenitor cells and causes significant morbidity and mortality in organ transplant recipients by disseminating to other organs from the bone marrow via leukocyteassociated viremia (1, 3, 4) . Further studies should examine developing a clinically relevant bone marrow transplantation protocol to deliver DNA sequence coding for M1GS into the bone marrow progenitor cells (eg, CD34ϩ cells) and whether M1GS RNA can be expressed and inhibit CMV infection in these cells, leading to the blockage of viral infection in leukocytes and viral dissemination in blood. These studies, in combination with further engineering of M1GS RNAs to increase their cleavage activity and specificity, will significantly facilitate the development of more active and effective RNase P ribozymes for gene-targeting applications, including therapy of human CMV infection.
Materials and Methods
Ribozyme, Substrate, and in Vitro Studies. The DNA sequence that encodes substrate Map39 was constructed by PCR using pGEM3zf(ϩ) as a template and oligonucleotides AF25 (5Ј-GGAATTCTAATACGACTCACTATAG-3Ј) and smAP (5Ј- 1, 3, 7, 10, 14 , and 21 days after infection, the animals (three mice per group) were killed. The salivary glands, lungs, spleens, and livers were collected and sonicated. The viral titers in the tissue homogenates were determined by standard plaque assays in NIH 3T3 cells. The limit of detection was 10 pfu/ml of the tissue homogenate. The viral titers represent the average obtained from triplicate experiments. The error bars indicate the standard deviation. Error bars that are not evident indicate that the standard deviation was less than or equal to the height of the symbols.
CGGGATCCGCCCGACTGAGGTAGACGCGGTGGTTCATCCTATAGTGAGTCG-TATTA-3Ј) as 5Ј and 3Ј primers, respectively. Plasmid pFL117 and pC102 contain the DNA sequence coding for M1 RNA and mutant C102 driven by the T7 RNA polymerase promoter (20, 31) . Mutant ribozyme C102 contains several point mutations (e.g., A347C348 3 C347U348, C353C354C355G356 3 G353G354A355U356) at the catalytic domain (P4 helix) (31) . The DNA sequences that encode ribozymes M1-1 and M1-2 were constructed by PCR using the DNA sequences of the M1 and C102 ribozymes as the templates and oligonucleotides AF25 and M1mAP (5Ј-CCCGCTCGAGAAAAAATGGTGCGTCTACCTCAGTCGGGTGTGGAATTGTG-3Ј) as 5Ј and 3Ј primers, respectively. M1GS RNAs and the Map39 mRNA substrate were synthesized in vitro by T7 RNA polymerase, and cleavage and binding assays were 
Expression of Ribozymes in Constructed Cell
Lines. NIH 3T3 cells expressing different ribozymes were constructed, and the expression of these ribozymes was assayed using Northern analyses, following procedures described previously (see SI Materials and Methods) (5, 20) .
Viral Infection and Assays for Viral
Gene Expression and Growth. T-25 flasks of cells (Ϸ10 6 cells) were either mock-infected or infected with MCMV, as described previously (5, 20) . The MOI is specified in Results. The infected cells were incubated for 8 -72 h. The RNA and protein samples were isolated from infected cells, and the expression of specific mRNAs and proteins were assayed by Northern and Western analyses, respectively, following procedures described previously (see SI Materials and Methods) (5, 20) .
To determine the level of the inhibition of viral growth, 5 ϫ 10 5 cells were either mock infected or infected with MCMV at an MOI of 1. The infection was carried out by incubating cells with DMEM in the absence or presence of viruses at 37°C for 90 min and then with fresh DMEM for different periods of time (5) . The cells and medium were harvested at 1, 2, 3, 4, and 5 days after infection, and viral stocks were prepared by adding 10% skim milk followed by sonication. The titers of the viral stocks were determined by performing plaque assays on NIH 3T3 cells (5) . The values obtained were the average of triplicate experiments.
Infection and Hydrodynamic Transfection of Animals. Four-to six-week-old CB17 SCID mice (Jackson Laboratory) were infected i.p. with 1 ϫ 10 4 pfu of MCMV (Smith strain). At 24 h after infection, different plasmid DNAs were delivered to these animals using a modified hydrodynamic transfection method (24 -26) . In these experiments, mice were first anesthetized with isoflurane, and 1-2 ml PBS (based on the injection volume/body-weight ratio) with or without 20 g of LXSN-M1GS DNA was then rapidly injected into the tail veins of the animals within 5-10 s by using a syringe with hypodermic needles of 24 -27 gauge size. The hydrodynamic transfection procedures were repeated every 72 h. The transfection efficiency was evaluated by detecting the expression of M1GS RNAs in the tissues (e.g., livers) using Northern analyses and examining the GFP staining of the transfected cells in the tissues using fluorescence microscopy. The GFP-expressing cassette sequence was included in the LXSN vector sequence. Consistent with previous hydrodynamic transfection reports (24 -26) , we regularly achieved a transfection efficiency of 60% in the livers and 30% in the spleens.
Analysis of Viral Virulence, Growth, and Gene Expression in SCID Mice. The animals were observed twice daily, the mortality of the infected animals was monitored for at least 41 days after infection, and the survival rates were determined.
To study viral growth and gene expression in mice, CB17 SCID mice were infected i.p. with 1 ϫ 10 4 pfu of each virus. The infected animals (at least three animals per group) were killed at 1, 3, 7, 10, 14, and 21 days after inoculation. The salivary glands, lungs, spleens, and livers were harvested and sonicated as a 10% (wt/vol) suspension in a 1:1 mixture of DMEM and 10% skim milk. Viral titers of the samples were determined using plaque assays as described previously (see SI Materials and Methods) (5) .
In gene expression experiments, tissues were homogenized and total RNA and proteins were then isolated following described procedures (5) . The expression of M1GS RNA and viral mRNA was determined using Northern analyses, whereas the expression of viral proteins was assayed using Western analysis.
